Cardiol Therapeutics

BRIEF

published on 11/22/2024 at 11:11, 29 days 3 hours ago

Cardiol Therapeutics Secures Buy Rating Amid Promising Trial Results

Clinical Trials BUY Rating Cardiol Therapeutics CardiolRx Drug Efficacy
PRESS RELEASE

published on 11/22/2024 at 11:06, 29 days 3 hours ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY
First Berlin Equity Research reaffirms BUY rating for Cardiol Therapeutics Inc. with USD8.50 price target based on positive final data for CardiolRx in treating recurrent pericarditis

Cardiol Therapeutics Inc First Berlin Equity Research BUY Rating Reaffirmed CardiolRx
BRIEF

published on 10/28/2024 at 15:51, 1 month 23 days ago

Cardiol Therapeutics Initiates Phase II/III Clinical Trial for Recurrent Pericarditis

Clinical Trial Cardiol Therapeutics CardiolRx Recurrent Pericarditis MAVERIC-2 Trial
PRESS RELEASE

published on 10/28/2024 at 15:46, 1 month 23 days ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates BUY recommendation for Cardiol Therapeutics Inc., initiating phase II/III clinical trial for recurrent pericarditis treatment with CardiolRx

Cardiol Therapeutics Inc First Berlin Equity Research Buy Recommendation Clinical Trial Pericarditis Treatment
BRIEF

published on 06/14/2024 at 14:57, 6 months 6 days ago

Cardiol Therapeutics Inc Receives Updated 'Buy' Rating from First Berlin Equity Research

BUY Rating Cardiol Therapeutics CardiolRx Recurrent Pericarditis Phase II Study
PRESS RELEASE

published on 06/14/2024 at 14:52, 6 months 6 days ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research increases Cardiol Therapeutics Inc's price target to USD8.50 in Buy recommendation after positive results from phase II trial of CardiolRx for recurrent pericarditis treatment

Cardiol Therapeutics Inc First Berlin Equity Research Buy Recommendation Phase II Trial CardiolRx
BRIEF

published on 02/27/2024 at 14:16, 9 months 22 days ago

Cardiol Therapeutics Receives FDA Orphan Drug Designation for CardiolRx

FDA Investment Orphan Drug Designation Cardiol Therapeutics Pericarditis
PRESS RELEASE

published on 02/27/2024 at 14:16, 9 months 22 days ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates BUY recommendation on Cardiol Therapeutics Inc. FDA grants Orphan Drug Designation for CardiolRx in pericarditis treatment. Positive phase II study results expected in Q2 2024

FDA Cardiol Therapeutics Inc First Berlin Equity Research Orphan Drug Designation Pericarditis
PRESS RELEASE

published on 01/19/2024 at 12:41, 11 months 2 days ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research has published an update on Cardiol Therapeutics Inc., reaffirming its BUY recommendation and maintaining the price target of USD 3.60. The report highlights the progress in patient recruitment for CardiolRx's two lead indications, acute myocarditis (AM) and recurrent pericarditis (RP), with expectations of significant near-term catalysts for the stock. Analyst Christian Orquera remains optimistic about the company's investment potential. For the full analysis, visit the link provided.

Cardiol Therapeutics Inc First Berlin Equity Research Buy Recommendation Patient Recruitment Investment Potential
PRESS RELEASE

published on 08/30/2023 at 15:06, 1 year 3 months ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy

Published on 12/21/2024 at 01:30, 12 hours 45 minutes ago

Quantum Biopharma Announces Closing of Second Tranche
Published on 12/21/2024 at 01:30, 12 hours 45 minutes ago

iMetal Resources Closes First Tranche of Previously Announced Non-Brokered Private Placement
Published on 12/21/2024 at 00:05, 14 hours 10 minutes ago

Chloeta Awarded GSA OASIS+ IDIQ Contract for Intelligence, Federal Civilian and Defense Support Services
Published on 12/21/2024 at 00:00, 14 hours 15 minutes ago

Amarc Announces Loan Extension
Published on 12/20/2024 at 23:30, 14 hours 45 minutes ago

Boron One Announces Extension to Early Warrant Exercise Incentive Program

View all ACCESSWIRE

Published on 12/21/2024 at 00:51, 13 hours 24 minutes ago

Acquisition of PSI Transcom GmbH by CHAPTERS platform Altamount Software GmbH
Published on 12/21/2024 at 00:45, 13 hours 30 minutes ago

EQS-Adhoc: PSI sells the Mobility business unit
Published on 12/20/2024 at 19:10, 19 hours 5 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 12/20/2024 at 18:56, 19 hours 19 minutes ago

CPI PROPERTY GROUP – Progress on Key Initiatives
Published on 12/20/2024 at 18:00, 20 hours 15 minutes ago

ARYZTA AG Announces New Board Technology Committee

View all EQS

Published on 12/21/2024 at 12:17, 1 hour 57 minutes ago

AXA announces the signing of a share purchase agreement with BNP Paribas relating to the sale of AXA IM
Published on 12/20/2024 at 18:00, 20 hours 15 minutes ago

Capital increase through exercise of subscription rights
Published on 12/20/2024 at 17:55, 20 hours 20 minutes ago

Disclosure of trading in own shares from 16/12/2024 to 20/12/2024
Published on 12/20/2024 at 14:00, 1 day ago

Safran: Woodward Signs Agreement to Acquire Safran’ s Electromechanical Actuation Business based in North America
Published on 12/19/2024 at 18:30, 1 day 19 hours ago

Share capital decrease by way of treasury shares cancellation

View all LES ECHOS COMFI WIRE

News